Every glutathione trial in the literature picked one route and lived with the consequences of that choice. Oral capsules above 3 g failed to raise plasma GSH meaningfully in a controlled pharmacokinetic study. IV push peaks within minutes and is cleared by gamma-glutamyl transpeptidase at the renal and hepatic beds inside an hour. Intranasal delivery exploits the olfactory pathway for CNS uptake in Parkinson patients. Nebulized GSH targets airway lining fluid in cystic fibrosis. Liposomal oral, sublingual, and orobuccal formulations exist precisely because intestinal hydrolysis defeats unprotected oral dosing. None of those trials picked their route for your indication, your absorption, your tolerance for injection, or whether you have airway disease, neurodegeneration, or a dermatologic concern.
Matching route to indication is the work a compounding pharmacy does for glutathione specifically. A prescriber who knows the clinical question can choose IV push when speed and systemic load matter, intramuscular for slower release, nebulized when the target is lung lining fluid, intranasal when the target is brain, sublingual or liposomal oral when the patient cannot tolerate needles, and topical when the target is skin. Dose, frequency, preservative profile, and pH all adjust to the patient. The FDA's 2019 alert on endotoxin-related events from poorly sourced injectable GSH makes the second compounding axis explicit: ingredient suitability and sterile preparation are part of the prescription, not assumptions about the supply chain.
This is what pharmacy looked like before mass manufacturing arrived. A doctor wrote the prescription, a pharmacist prepared it for that named patient, and the route was chosen for the body it was going into. Compounded glutathione is that older arrangement, kept honest by modern sterility, ingredient, and traceability discipline.
In brief
Glutathione Explained
Glutathione is the body's most abundant endogenous antioxidant, a tripeptide of glutamate, cysteine, and glycine present in nearly every cell at millimolar concentrations 2852.
Researchers have evaluated supplemental glutathione across several routes (oral, liposomal oral, sublingual, intranasal, intravenous, nebulized, topical) and several research contexts (Parkinson disease, nonalcoholic fatty liver disease, cystic fibrosis, dermatology, healthy-adult biomarker studies) 11125. The cellular biochemistry is well characterized; clinical evidence varies by route and indication and is not uniformly established across uses 25.
RonanRx-compounded glutathione is dispensed only on a patient-specific prescription written by a licensed doctor for an identified patient. RonanRx does not sell glutathione directly to patients 689.
Mechanism well established; clinical efficacy is indication- and route-specific and remains mixed
FDA-approval status
Not FDA-approved as a drug for any specific indication; N-acetylcysteine (a precursor) is FDA-approved for acetaminophen overdose
Compounded under
503A, patient-specific prescription only
Important compounding caution
FDA documented endotoxin-related adverse events from certain compounded sterile L-glutathione injections; ingredient quality and sterility are critical
Prescription review
Patient-Specific Prescription Only
Glutathione on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Glutathione?
Glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is a low-molecular-weight tripeptide synthesized de novo in every nucleated cell 19. Total body content is several grams, with the highest concentrations in the liver and notable pools in lung lining fluid, kidney, and brain.
Two redox states exist: reduced glutathione (GSH) and oxidized glutathione disulfide (GSSG) 8. The GSH:GSSG ratio is a primary indicator of cellular redox status across tissues.
Glutathione is structurally distinct from the standard peptide bond by virtue of its γ-glutamyl linkage, a feature that protects it from cleavage by most peptidases except gamma-glutamyl transpeptidase (GGT), which initiates extracellular GSH catabolism 8917.
How it works
How Glutathione Works
Class
Tripeptide antioxidant
First studied
1880s biochemistry
Common forms
Injection or oral liposomal
Compounding category
503A, patient-specific prescription
Glutathione is the substrate for the glutathione peroxidase family of enzymes, which reduce hydrogen peroxide and lipid hydroperoxides to water and the corresponding alcohols. The oxidized disulfide product is recycled back to GSH by glutathione reductase using NADPH derived from the pentose phosphate pathway.
Glutathione also conjugates electrophilic xenobiotics through glutathione S-transferases (GSTs), enabling Phase II liver detoxification. The resulting glutathione conjugates are exported by multidrug resistance-associated proteins (MRPs) and excreted in bile or urine 8919.
Beyond redox cycling and conjugation, GSH participates in protein S-glutathionylation as a reversible post-translational modification, regulates apoptosis through mitochondrial GSH pools, supports immune cell function, and modulates redox-sensitive signaling pathways 141516.
Research history
Glutathione Research History
Glutathione was isolated and characterized as a sulfur-containing peptide by F. Gowland Hopkins in the early 1920s. Decades of biochemical work characterized its synthesis, redox cycling, conjugation chemistry, and the gamma-glutamyl cycle described by Alton Meister and colleagues from the 1960s onward 1718.
Human pharmacokinetics of exogenous glutathione were first characterized in the early 1990s. Aebi and colleagues reported high-dose intravenous glutathione PK and downstream effects on plasma and urine cyst(e)ine in adult volunteers 34. Witschi and colleagues evaluated the systemic availability of oral glutathione, finding that single oral doses up to 3 g did not raise plasma glutathione meaningfully, a key result that motivated subsequent work on liposomal and sublingual formulations 35. Mechanistic absorption studies in animals characterized intact-tripeptide transport across the small intestine and the role of alpha-adrenergic regulation 36.
Clinical investigation as an exogenous therapy began shortly after. A small open-label trial in early Parkinson disease 1 reported symptomatic improvement on UPDRS following intravenous glutathione, prompting follow-up work. A subsequent placebo-controlled crossover RCT failed its primary endpoint: while both arms improved, the between-group difference was not statistically significant 2, an important honest negative result. Two intranasal Parkinson trials by Mischley and colleagues (2015 phase I/IIa 3, 2017 phase IIb 5) extended that work to a non-invasive route, with both glutathione and placebo arms improving similarly 21. A separate pharmacologic study confirmed CNS uptake of intranasal glutathione 4919.
Outside Parkinson research, an open-label NAFLD pilot evaluated oral glutathione 300 mg daily over four months 6. Earlier descriptive work documented disturbances in trace elements and oxidative-stress markers in chronic nonalcoholic liver disease 33, and pediatric work characterized plasma cysteine/homocysteine elevations correlating with severity in pediatric NAFLD 46. Healthy-adult oral supplementation studies have evaluated plasma and lymphocyte GSH biomarkers across capsule 1011, liposomal 12, sublingual 13, and orobuccal 50 forms. Cystic fibrosis trials examined inhaled GSH for pulmonary outcomes 252439, with a Cochrane review identifying limited high-quality long-term data 23. A separate nebulized-glutathione trial in mild asthma documented bronchoconstriction in some subjects, an important route-specific safety signal 38. The aerosol delivery concept was first explored in idiopathic pulmonary fibrosis a decade earlier 3751.
Oncology supportive-care research evaluated intravenous glutathione as a chemoprotectant. A double-blind RCT in women receiving cisplatin for ovarian cancer reported reduced toxicity and improved quality of life 40, and a placebo-controlled RCT in colorectal cancer reported reduced oxaliplatin-induced peripheral neuropathy 41. Precursor strategies, N-acetylcysteine 26, and combined glycine + cysteine supplementation, have been pursued in parallel. Sekhar and colleagues demonstrated that glutathione synthesis is deficient in older adults and in uncontrolled diabetes and can be restored by dietary cysteine + glycine 4243; the GlyNAC formulation (glycine + N-acetylcysteine) advanced through a pilot 44 and a randomized clinical trial in older adults 45 reporting improvements in oxidative-stress and aging-hallmark biomarkers. A small autism trial of oral glutathione 47 reported no significant clinical efficacy 308.
Dermatology research has assessed oral, sublingual, and topical glutathione as a skin-lightening agent 4849. A 2018 critical review specifically addressed IV glutathione marketed for skin lightening, noting absence of high-quality efficacy data and significant safety concerns 28; a 2025 systematic review came to similar conclusions 2927. Indian and Philippine regulatory authorities have explicitly warned against IV glutathione for cosmetic skin-lightening use.
Foundational and contemporary reviews of glutathione's role in cellular redox biology continue to inform the field 27.
FDA issued a 2019 alert describing endotoxin-related adverse events in patients who received compounded sterile injectable L-glutathione that had been prepared from an ingredient that was not suitable for sterile injectable compounding 52. The alert is a key reference for distinguishing compound-related literature from compounding-quality risks.
Timeline
Glutathione Timeline
1920sHopkins isolates and characterizes glutathione as a sulfur-containing peptide
1960s, 80sMeister and colleagues characterize the gamma-glutamyl cycle, GSH synthesis enzymes, and mitochondrial GSH biology 1718
1991Aebi et al characterize high-dose IV glutathione pharmacokinetics in humans (Eur J Clin Invest); Borok et al publish aerosolized GSH study in idiopathic pulmonary fibrosis 3437
1992Witschi et al publish 'The systemic availability of oral glutathione', foundational PK finding that single oral doses up to 3 g do not meaningfully raise plasma GSH 35
1995Lomaestro & Malone publish a clinical pharmacotherapy review of glutathione in health and disease 7
1996Sechi et al publish small open-label IV glutathione trial in early Parkinson disease 1
1997Smyth et al publish double-blind RCT of IV glutathione as cisplatin chemoprotectant in ovarian cancer; Marrades et al document bronchoconstriction from nebulized GSH in mild asthma 4038
1999Roum et al demonstrate that aerosolized GSH suppresses lung epithelial surface oxidant production in cystic fibrosis 39
2002Cascinu et al publish randomized placebo-controlled trial of IV glutathione for oxaliplatin neuroprotection in colorectal cancer 41
2004Wu et al publish 'Glutathione metabolism and its implications for health' in J Nutrition 9
2005Bishop et al publish pilot study of inhaled buffered reduced glutathione in cystic fibrosis 25
2007Atkuri et al publish 'N-Acetylcysteine, a safe antidote for cysteine/glutathione deficiency' (Curr Opin Pharmacol) 26
2009Hauser et al publish randomized double-blind crossover IV glutathione in Parkinson disease, primary endpoint not met 2
2011Sekhar et al publish foundational stable-isotope studies showing deficient GSH synthesis in aging and uncontrolled diabetes, restored by cysteine + glycine; Kern et al publish small glutathione RCT in autism (no significant clinical effect) 424347
2012Arjinpathana & Asawanonda publish randomized placebo-controlled trial of oral glutathione as a skin-lightening agent in Thai adults 48
2009Ballatori et al publish reviews of GSH dysregulation in human diseases and plasma membrane GSH transporters 1920
2013Lu publishes 'Glutathione synthesis' review in Biochim Biophys Acta 8
2015Mischley et al publish phase I/IIa intranasal glutathione study in Parkinson disease 3
2015Richie et al publish randomized controlled trial of oral glutathione supplementation in healthy adults 11
2017Mischley et al publish phase IIb intranasal glutathione study in Parkinson disease; Honda et al publish open-label oral glutathione pilot in NAFLD 56
2017Sies, Berndt & Jones publish 'Oxidative Stress' in Annual Review of Biochemistry, contemporary unifying framework 51
2018Sonthalia et al publish critical review of IV glutathione for skin lightening, 'a regnant myth or evidence-based verity?' 28
2019FDA issues alert on compounded sterile injectable L-glutathione following endotoxin-related adverse events 52
2021Aoyama publishes 'Glutathione in the Brain' review in Int J Mol Sci; Kumar et al publish GlyNAC pilot in older adults 2144
2023Kumar et al publish randomized clinical trial of GlyNAC (glycine + NAC) in older adults, improvements in glutathione status, oxidative stress, mitochondrial function, and aging-hallmark biomarkers 45
2025Sarkar et al publish systematic review of glutathione as a skin-lightening agent in melasma 29
Natural role
Biological Role of Glutathione
Endogenous glutathione concentrations decline with age, oxidative stress, certain chronic disease states, and inadequate sulfur-amino-acid intake 31. Restoring GSH stores is the therapeutic rationale for both precursor supplementation (NAC) and direct GSH administration.
Disorders of GSH homeostasis, whether acquired (alcoholic and nonalcoholic liver disease, HIV, sepsis, certain cancers) or genetic (rare deficiencies of GCL or glutathione synthetase), are associated with increased susceptibility to oxidative injury and altered drug metabolism 8919.
GSH is also central to cellular handling of heavy metals, electrophilic environmental toxicants, and reactive products of normal lipid and amino-acid metabolism 32. Its breadth of function is why it is sometimes called a 'master antioxidant' in lay literature, though that label oversimplifies a more nuanced biology.
Studied in small clinical trials with mixed results; the only placebo-controlled IV RCT failed its primary endpoint.
Open-label and small randomized studies have investigated IV and intranasal glutathione as adjunctive therapy. The original Sechi 1996 open-label trial 1 reported UPDRS improvement in 9 patients with early Parkinson disease. The Hauser 2009 randomized double-blind crossover 2 found no statistically significant difference vs placebo on UPDRS, an important honest negative result that tempered enthusiasm. Mischley 2015 phase I/IIa 3 and 2017 phase IIb 5 studies of intranasal glutathione both showed improvement in active and placebo arms with no statistically significant between-group difference. A pharmacologic study by the same group documented CNS uptake of intranasal glutathione by MRS 4, establishing route feasibility independent of efficacy. Effect sizes across the literature are modest and inconsistent; no large pivotal trial has demonstrated efficacy.
Early open-label evidence; no controlled replication.
An open-label single-arm Japanese pilot 6 reported reduction in ALT and other liver markers with daily oral glutathione 300 mg over four months in 29 patients non-responsive to lifestyle intervention. Earlier descriptive work documented disturbances in trace-element and oxidative-stress markers in chronic nonalcoholic liver disease 33, and a pediatric NAFLD cohort showed plasma cysteine and homocysteine elevations correlating with severity of liver damage 46. Controlled replication of the open-label pilot in a larger sample has not been completed.
Inhaled glutathione has been studied in cystic fibrosis based on the observation that lung epithelial lining fluid in CF is glutathione-deficient. Roum and colleagues 39 reported that aerosolized glutathione suppresses oxidant production by lung epithelial surface inflammatory cells in CF. A pilot study by Bishop and colleagues 25 reported clinical-status improvement with inhaled buffered reduced glutathione, and a follow-up unblinded study by Visca and colleagues 24 observed improvement in selected clinical markers. A 2013 Cochrane review 23 of nebulized and oral thiol derivatives (including glutathione) for cystic fibrosis identified some short-term lung-function effects but limited high-quality long-term data.
Marrades and colleagues 38 reported that nebulized glutathione induced bronchoconstriction in some patients with mild asthma. This is a route-specific safety signal that does not invalidate inhaled GSH use in CF (where the underlying epithelial physiology differs) but does constrain extrapolation to asthma and other airway populations. The 1991 Borok et al. trial of aerosolized GSH in idiopathic pulmonary fibrosis 37 established earlier pulmonary delivery feasibility.
Oncology supportive care (chemoprotection) emerging
Moderate-quality RCT evidence for cisplatin and oxaliplatin toxicity reduction; not standard of care.
Smyth and colleagues 40 reported a double-blind randomized trial of IV glutathione in women receiving cisplatin for ovarian cancer; glutathione was associated with reduced toxicity and improved quality of life without compromising tumor response. Cascinu and colleagues 41 reported a placebo-controlled RCT of IV glutathione in patients receiving oxaliplatin-based therapy for advanced colorectal cancer, demonstrating reduced oxaliplatin-induced peripheral neuropathy. These are among the strongest controlled efficacy signals in the glutathione clinical literature, but the findings have not driven changes in standard oncology practice and theoretical concerns about antioxidant interference with chemotherapy oxidative mechanisms remain.
Glutathione precursor strategies (NAC and GlyNAC) well studied
Precursor supplementation raises body GSH in deficiency states; clinical outcomes still under study.
N-acetylcysteine (NAC) is the clinically established cysteine precursor and remains the FDA-approved antidote for acetaminophen overdose 26; its dose-limiting use in acetaminophen toxicity is the mechanistic and regulatory proof that pharmacologic GSH precursor supplementation reaches the liver in clinically meaningful quantities. Sekhar and colleagues identified that glutathione synthesis is also glycine-limited in older adults 42 and in patients with uncontrolled diabetes 43, and that combined cysteine + glycine supplementation restored GSH synthesis rates and lowered oxidative-stress biomarkers. Building on that work, Kumar and colleagues advanced the GlyNAC formulation (glycine + NAC) through a pilot 44 and a randomized clinical trial in older adults 45, reporting improvements in glutathione status, oxidative-stress markers, mitochondrial function, inflammation, and several aging-related physical-function endpoints.
Kern and colleagues 47 conducted a small clinical trial of oral and transdermal glutathione supplementation in children with autism spectrum disorder. The trial did not demonstrate statistically significant clinical efficacy on autism-specific outcomes; the study is cited primarily as a documentation of negative findings in this population.
Route-specific evidence of measurable change in body GSH stores.
Randomized trials in healthy adults have evaluated standard oral capsule 1011, oral liposomal 12, sublingual 13, and orobuccal 50 glutathione. These studies report measurable elevations in plasma, erythrocyte, or lymphocyte GSH and in some markers of oxidative stress, with magnitudes that vary by formulation. The clinical relevance of these biomarker shifts in otherwise healthy adults is not established.
Studied in dermatology research; regulatory and ethical framing requires care.
Oral, sublingual, topical, and (controversially) IV glutathione have been investigated for skin-lightening and melasma effects. A small Thai oral RCT 48 reported modest skin-lightening effects with 500 mg/day oral glutathione for 4 weeks. An open-label single-arm Filipino study 49 reported similar effects with a novel oral preparation. A pharmacokinetic-focused orobuccal trial 30 documented enhanced absorption via mucosa. The 2018 critical review of IV glutathione for skin lightening 28 catalogued the regulatory and safety concerns, including FDA enforcement against IV skin-lightening products and Philippine and Indian regulatory warnings, and concluded that the IV-glutathione skin-lightening market is not supported by high-quality efficacy evidence and operates outside appropriate compounded-medication use 27. A 2025 systematic review 29 reached similar conclusions. RonanRx does not support compounded IV glutathione for cosmetic skin lightening.
Oxidative stress and antioxidant support well studied
Mechanism well characterized; clinical outcome data limited.
Glutathione's role as the principal cellular antioxidant is established through decades of biochemical research 89715. Whether exogenous administration meaningfully changes clinical outcomes in oxidative-stress conditions remains an active research question, the field has consistent biomarker data but limited patient-relevant outcomes data outside the specific indications listed above 19513116.
Compounded use
Compounded Glutathione (503A)
Compounded glutathione is dispensed under 503A on a patient-specific prescription. Common preparations include intravenous and intramuscular injectable solutions, intranasal sprays, oral liposomal capsules, sublingual troches or sprays, and nebulized solutions for inhaled use.
RonanRx prescribes glutathione only when the prescribing doctor identifies a patient-specific clinical need that an FDA-approved product is not medically appropriate to address. Compounded glutathione is not promoted as a generic substitute for any FDA-approved drug, and is not sold direct-to-consumer 53.
Formulations and routes
Glutathione Formulations and Routes
Form
Concentration
Description
Injectable solution
200 mg/mL
IV, IM, or SC administration; preservative-free single-dose vials prepared under USP <797> sterile-compounding standards
Intranasal spray
100 mg/mL
Metered-dose nasal spray; route used in published Parkinson disease research35
Oral liposomal capsule
500 mg
Phospholipid-encapsulated capsule; designed to reduce gastrointestinal hydrolysis12
Sublingual troche / spray
varies
Sublingual administration; evaluated against oral capsule and NAC in head-to-head bioavailability work13
Nebulizer solution
200 mg/mL
Sterile solution for use in compatible nebulizers; route used in cystic fibrosis research2524
Oral capsule (non-liposomal)
250, 1000 mg
Standard oral capsule; route used in healthy-adult RCT1110
Routes used in published literature: intravenous, intramuscular, subcutaneous, intranasal, oral, sublingual, inhalation, topical.
Doses listed reflect published clinical-trial protocols, not RonanRx prescribing recommendations. The prescribing doctor selects route, dose, and frequency based on the patient's clinical context, indication, and goals.
Doses listed should not be presented to patients as instructions. Patient instructions originate from the prescribing physician's prescription, not from this educational page.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Glutathione Safety
Safety overview
Across published clinical trials, exogenous glutathione has been generally well-tolerated at studied doses. Reported adverse effects have been mild and infrequent and include nausea, lightheadedness, and rare hypersensitivity reactions with parenteral administration.
Safety considerations for compounded glutathione fall into two distinct categories that should not be conflated 125. The first is **compound-related safety**: the literature signal for the molecule itself, summarized below. The second is **compounding-quality safety**: the FDA's 2019 alert documented endotoxin-related adverse events in patients who received compounded sterile injectable L-glutathione prepared from an ingredient that was not suitable for sterile injectable compounding 52. That alert is a quality-of-preparation signal, not a compound-toxicity signal, and motivates the operational discipline (USP <797> compliance, sterility testing, lot traceability, ingredient suitability) covered in the compounding section below.
Contraindications
Honest gap. No formal contraindications established for compounded glutathione at typical clinical-trial doses. Documented hypersensitivity to any component of a particular preparation is a relative contraindication for parenteral use of that preparation.
Honest gap. No clinically significant drug-drug interactions established. Theoretical concern that high-dose antioxidants may interfere with chemotherapy oxidative mechanisms; oncology patients should consult their treating physician before starting any glutathione preparation.
Searched: PubMed, DailyMed on 2026-05-07 · terms glutathione drug-drug interactions.
Adverse events
Across reviewed clinical trials, adverse events were mild and uncommon. Hypersensitivity reactions to IV glutathione have been reported in the broader literature; preservative-free sterile formulations are preferred for parenteral use.
FDA documented endotoxin-related reactions (nausea, vomiting, lightheadedness, chills, body aches, sneezing, hypotension, dyspnea, sudden chills, fever, shaking) in patients who received compounded IV L-glutathione 1400 mg or 2400 mg from preparations later found to contain excessive bacterial endotoxin from an ingredient that was not suitable for sterile injectable compounding 52. These events are not intrinsic to glutathione; they reflect failures of compounded-sterile-preparation quality control 2.
Monitoring
Monitoring Glutathione Therapy
Routine laboratory monitoring is not required for typical compounded use. The prescribing doctor may monitor disease-specific markers (for example, ALT in liver indications, UPDRS scoring in Parkinson clinical follow-up) at clinically appropriate intervals.
Patients receiving sterile parenteral glutathione should report any signs of acute hypersensitivity (rash, dyspnea, hypotension) or post-infusion symptoms (chills, fever, body aches, lightheadedness) to the prescribing physician promptly, particularly given the FDA-documented endotoxin-related adverse-event pattern 652.
Evidence quality
Glutathione Evidence Quality
The biochemistry of glutathione synthesis, redox cycling, conjugation, and inter-tissue handling is well established by decades of biochemical and cell-biology research 8919. Clinical evidence for exogenous administration is more variable 27. Most clinical trials are small, often open-label, and use crossover or short-duration designs 13. Larger, well-controlled trials with patient-relevant outcomes are needed before firm efficacy conclusions can be drawn for any clinical indication 50.
Evidence by indication: Parkinson disease, the original Sechi 1996 open-label trial 1 reported UPDRS improvement, but the only placebo-controlled RCT 2 did not meet its primary endpoint, and two intranasal trials 35 showed equivalent improvement in glutathione and placebo arms. Net: no positive pivotal trial. NAFLD, single open-label pilot 6, plus descriptive oxidative-stress/sulfur-amino-acid work 3346; no controlled replication. Cystic fibrosis, pilot and open-label studies 252439 plus a Cochrane review 23 identifying limited high-quality long-term data; a separate trial of nebulized GSH in mild asthma documented bronchoconstriction in some subjects 38, a route-specific safety signal that is relevant when extrapolating inhaled GSH outside CF populations. Healthy-adult biomarker studies, multiple randomized trials demonstrate route-dependent measurable changes in body GSH stores; clinical relevance of those changes in healthy adults is not established 481112. Oncology supportive care, moderate-quality RCTs report reduced cisplatin toxicity 40 and reduced oxaliplatin neuropathy 41; these are the strongest controlled efficacy signals in the literature but have not driven changes in standard oncology practice 10. Precursor strategies, randomized data on glycine + cysteine 4243 and the GlyNAC formulation 4445 show consistent biomarker effects in deficiency states. Autism, a small RCT 47 did not demonstrate clinical efficacy 4930. Dermatology, modest, often transient effects in skin-lightening research; the 2018 critical review 28 and 2025 systematic review 29 both conclude the cosmetic compounded-IV market sits outside appropriate use of compounded medications and is not supported by high-quality efficacy evidence 51.
Daily oral glutathione 300 mg associated with reductions in ALT and selected hepatic-fat markers in patients non-responsive to lifestyle intervention 6.
Characterized rapid post-infusion decline in plasma GSH and concurrent elevation of plasma and urinary cyst(e)ine, consistent with GGT-mediated catabolism 34. Foundational IV-PK reference.
Single oral doses up to 3 g did not raise plasma glutathione meaningfully 35. Key motivating result for liposomal, sublingual, and orobuccal formulation work.
Oral glutathione 500 mg twice daily did not significantly change blood glutathione or oxidative-stress biomarkers in healthy adults, a negative result that complemented the Richie 2015 RCT and Witschi 1992 PK findings 10.
IV glutathione reduced cisplatin toxicity and improved quality of life without compromising tumor response 40. Strongest controlled efficacy signal in oncology supportive care literature.
Nebulized GSH caused bronchoconstriction in mild-asthma subjects, a route-specific safety signal relevant when extrapolating inhaled GSH outside CF populations 38.
Demonstrated that aerosolized GSH reduces airway oxidant burden in CF, supporting the mechanistic rationale for the Bishop 2005 and Visca 2008 pilot work 39.
Mechanistic clinical study with stable-isotope GSH-synthesis measurement
8 elderly + 8 young controls (initial cohort)
2 weeks supplementation
Older adults had deficient GSH synthesis rates which were normalized by 2 weeks of cysteine + glycine supplementation, with concurrent reduction in oxidative-stress biomarkers 42. Foundational paper for precursor strategies in aging.
Patients with uncontrolled type 2 diabetes had deficient GSH synthesis which was restored by combined cysteine + glycine supplementation, with parallel reductions in oxidative-stress markers 43.
GlyNAC supplementation in older adults improved glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, and physical-function and cognitive measures vs control 45. Largest controlled trial of a glutathione-precursor strategy to date.
Pilot data supporting the GlyNAC randomized trial; documented restoration of GSH synthesis and improvement in multiple oxidative-stress biomarkers and aging hallmarks 44.
Oral and transdermal glutathione increased plasma cysteine and sulfate but did not produce statistically significant improvement on autism-specific clinical outcomes 47.
Oral glutathione 500 mg/day produced modest skin-lightening effects vs placebo in Thai adults; effect size was small and transient 48. Frequently cited Thai-population reference in dermatology literature.
Reported skin-lightening effects with a novel oral preparation 49. Cited in the regulatory context that drove Philippine FDA warnings about IV-glutathione skin-lightening products.
Mechanism detail
Detailed Mechanism of Glutathione
GSH synthesis occurs in two ATP-dependent steps 8. Glutamate-cysteine ligase (GCL, the rate-limiting enzyme; previously known as γ-glutamylcysteine synthetase) catalyzes the formation of γ-glutamyl-cysteine from L-glutamate and L-cysteine. Glutathione synthetase then ligates glycine to form the tripeptide. Cysteine availability typically limits the rate of synthesis, which is why N-acetylcysteine (a cell-permeant cysteine precursor) is used clinically when accelerated GSH replenishment is needed 26. Glycine availability is a secondary constraint identified in human metabolic studies; combined glycine + cysteine supplementation restores deficient GSH synthesis in older adults and in patients with uncontrolled diabetes 4243, a finding that motivated the GlyNAC (glycine + N-acetylcysteine) precursor strategy now in randomized clinical trials 444514.
The mitochondrial GSH pool is functionally distinct from the cytosolic pool 18: GSH is synthesized only in the cytosol but is transported into mitochondria by dedicated carriers, where it serves as the principal antioxidant against the high reactive-oxygen-species flux of oxidative phosphorylation 14. Depletion of mitochondrial GSH is a common feature of cellular injury and apoptosis induction 22.
Plasma membrane glutathione transporters and gamma-glutamyl transpeptidase (GGT) together regulate extracellular GSH turnover 2014. The 'gamma-glutamyl cycle' described by Meister couples extracellular GSH catabolism to amino-acid uptake and intracellular resynthesis 17. In vivo, infused GSH has a short plasma half-life, Aebi and colleagues documented rapid post-infusion declines following IV doses with concurrent elevation of plasma and urinary cyst(e)ine, consistent with GGT-mediated catabolism at the renal and hepatic vascular beds 34.
Intestinal absorption of intact glutathione is limited; in rat small intestine, sodium-independent transport is regulated by alpha-adrenergic input 36. In humans, single oral doses up to 3 g did not raise plasma glutathione meaningfully in a controlled PK study 35, establishing the rationale for liposomal encapsulation 12, sublingual delivery 13, and orobuccal formulations 50 that bypass first-pass intestinal hydrolysis 14.
In the brain, astrocytes synthesize and export GSH precursors used by neurons for their own GSH synthesis 21; this astrocyte-to-neuron support is a recognized neuroprotective mechanism and has motivated interest in glutathione (and its precursors) in neurodegeneration research 14. Intranasal delivery exploits the olfactory and trigeminal pathways to bypass first-pass metabolism and the blood-brain barrier; Mischley and colleagues documented CNS uptake of intranasal glutathione in Parkinson disease patients using brain MRS 4.
Oxidative stress as a unifying concept, defined as a disruption of redox signaling and control, encompasses the biology that connects glutathione status to disease 5114. The GSH:GSSG ratio remains the most widely used single biomarker of cellular redox state, though its interpretation requires attention to compartmentalization between cytosolic, mitochondrial, and extracellular pools.
Pharmacology
Glutathione Pharmacokinetics & Pharmacodynamics
Pharmacokinetics
Intravenous glutathione has a short plasma half-life on the order of 10 minutes due to rapid hydrolysis by gamma-glutamyl transpeptidase at the renal and hepatic vascular beds; the canonical human IV-PK reference is Aebi and colleagues 34, who documented rapid post-infusion plasma decline with concurrent rise in plasma and urinary cyst(e)ine. Intracellular glutathione has a much longer turnover, hours to days depending on tissue 8.
Standard oral glutathione bioavailability has historically been considered very low because of gastrointestinal hydrolysis and limited intestinal transport of the intact tripeptide. The foundational human PK study 35 showed that single oral doses up to 3 g did not raise plasma glutathione meaningfully. Mechanistic absorption work in animals characterized intact-tripeptide transport across the small intestine 36. Subsequent randomized trials of standard capsule 1011, liposomal 12, sublingual 13, and orobuccal 50 forms have shown measurable but route-dependent elevations in body GSH stores, with the Allen 2011 trial of unencapsulated oral GSH being a notable negative result that reinforces the Witschi finding.
Intranasal glutathione has been shown to enter the central nervous system in pharmacologic studies in Parkinson disease populations 4, supporting the feasibility of bypassing first-pass and gut metabolism for CNS-targeted use. Inhaled (nebulized) delivery achieves direct airway exposure and has been studied in cystic fibrosis 3925 and historically in pulmonary fibrosis 37; the asthma bronchoconstriction signal 38 is a reminder that pulmonary delivery is not pharmacokinetically interchangeable across airway populations.
Pharmacodynamics
Pharmacodynamic effects depend on the target tissue's ability to take up exogenous GSH or its hydrolysis products (cysteine, glutamate, glycine) and resynthesize intracellular glutathione 8942.
Direct GSH supplementation, NAC (cysteine donor), and other precursor strategies all converge on raising tissue GSH but differ in distribution and redox kinetics 26. NAC's clinical proof-of-mechanism is its FDA-approved use as an antidote for acetaminophen toxicity, where it replenishes hepatic GSH stores depleted by NAPQI conjugation. The combined cysteine + glycine (and the GlyNAC formulation) precursor data in older adults and diabetes establish that glycine availability is a secondary rate-limit in some deficiency states 434445. The choice between direct GSH and precursor strategies is route- and indication-dependent and is the prescribing physician's clinical decision.
Comparative formulations
Comparing Glutathione Formulations
Standard oral capsules, liposomal oral capsules, and sublingual forms differ in absorption pathway 12. Liposomal encapsulation is designed to protect the tripeptide from gastrointestinal hydrolysis; sublingual delivery aims to bypass first-pass metabolism. Head-to-head studies 13 and standalone trials 11 report measurable but route-dependent body-GSH elevations.
Parenteral routes (IV, IM, SC) produce rapid plasma elevations but with short plasma half-life, since gamma-glutamyl transpeptidase efficiently hydrolyzes circulating GSH. Intranasal delivery has been characterized as a CNS-targeted alternative to IV in Parkinson research, with documented CNS uptake in Mischley 2016 4.
Inhaled (nebulized) glutathione targets airway lining fluid in pulmonary indications such as cystic fibrosis 2523. The 2013 Cochrane review concluded that high-quality long-term data remain limited.
RonanRx supports formulations consistent with documented clinical literature and 503A scope 24. The selection of formulation for a given patient is the prescribing doctor's decision.
Storage
Glutathione Storage and Handling
Compounded glutathione injectable solutions are typically stored refrigerated (2, 8 °C) and protected from light to minimize oxidation of the thiol group. Beyond-use dates depend on the formulation and preservative system; refer to the dispensing pharmacy's labeling for the specific preparation received.
Oral capsules and sublingual forms are stored per package labeling, typically at controlled room temperature with desiccant where indicated. Inhalation solutions follow the same refrigeration and light-protection considerations as injectables.
RonanRx operations
Glutathione Compounding & Operations
503A compounding
RonanRx prepares glutathione under 503A on a patient-specific prescription written by a licensed prescribing physician for an identified patient, consistent with section 503A of the Federal Food, Drug, and Cosmetic Act 53.
Bulk drug substance is sourced from FDA-registered API suppliers, and ingredient suitability for the intended formulation pathway (including suitability for sterile injectable compounding when applicable) is verified before use. Finished sterile preparations follow USP <797> standards. This process is the operational answer to the FDA 2019 glutathione alert: the alert documented harm from preparations whose ingredient was not suitable for sterile injectable compounding, and the appropriate response is rigorous ingredient and sterility control rather than withdrawal from the legitimate 503A scope 52.
Pharmacist review
Each prescription is reviewed by a licensed pharmacist before dispensing. Review covers prescribed strength, route, formulation suitability, patient-specific contraindications based on the prescription record, ingredient compatibility, and label accuracy.
The pharmacist also confirms the prescribed indication is consistent with 503A use rather than direct-to-consumer or office-stock distribution 53.
Quality and traceability
Every compounded preparation carries a lot number tied to the prescription record. Sterility, potency, and endotoxin testing for sterile preparations follow USP <797> guidelines, with documentation retained per state board of pharmacy requirements 52. Endotoxin testing in particular addresses the failure mode documented in FDA's 2019 alert.
Cold chain
Injectable and inhalation glutathione preparations ship in temperature-controlled packaging with a temperature indicator. Patients are advised to refrigerate immediately on receipt and to contact the pharmacy if temperature integrity is in doubt.
FAQ
Frequently Asked Questions About Glutathione
Is glutathione FDA-approved?
No. Glutathione itself is not FDA-approved as a drug for any specific indication 53. The closely related N-acetylcysteine (NAC), a glutathione precursor, has FDA-approved use in acetaminophen overdose. Compounded glutathione is dispensed under 503A on patient-specific prescriptions 26. Compounded drugs are not FDA-approved.
What conditions has glutathione been studied in?
Published clinical investigation has focused on Parkinson disease (small RCTs with mixed results), nonalcoholic fatty liver disease (one open-label pilot), cystic fibrosis (pilot studies and a Cochrane review), healthy-adult biomarker studies (multiple RCTs), and dermatology-related skin-lightening contexts 12523. Trial sizes are mostly small and results are mixed; cellular biochemistry is well characterized 11286.
How is glutathione administered?
Routes used in clinical trials and 503A compounding include intravenous, intramuscular, subcutaneous, intranasal, oral (standard and liposomal capsules), sublingual, inhaled (nebulized), and topical 111213. The prescribing doctor selects the route based on clinical context 525.
Why is oral glutathione thought to be poorly absorbed?
Standard oral glutathione is broken down by gastrointestinal enzymes before absorption, and intestinal transport of the intact tripeptide is limited 101112. Liposomal encapsulation and sublingual forms have been studied as workarounds, with measurable but route-dependent body-GSH elevations in randomized trials 13.
Is compounded IV glutathione safe?
Compound-related safety has been generally good across clinical trials. However, FDA documented endotoxin-related adverse events in patients who received compounded sterile injectable L-glutathione that had been prepared from an ingredient unsuitable for sterile injectable compounding 52. Those events are a quality-of-preparation signal, not a compound-toxicity signal. The appropriate response is rigorous ingredient suitability, sterility, endotoxin testing, and lot traceability, covered in the operations section above.
Does RonanRx sell glutathione directly to patients?
No. Compounded glutathione, if dispensed, requires a patient-specific prescription written by a licensed doctor for an identified patient and a route-specific feasibility review by a pharmacist. RonanRx is not a direct-to-consumer storefront for glutathione or any other compounded substance 53.
What about glutathione precursors, NAC and GlyNAC?
N-acetylcysteine (NAC) is a cysteine precursor with FDA-approved use as an antidote for acetaminophen overdose; that use is mechanistic proof that pharmacologic GSH precursor supplementation reaches the liver in clinically meaningful quantities 26. Sekhar and colleagues identified that combined glycine + cysteine supplementation restores deficient GSH synthesis in older adults and in patients with uncontrolled diabetes 4243. The GlyNAC formulation (glycine + NAC) has been studied in a pilot and a randomized clinical trial in older adults reporting improvements in glutathione status, oxidative-stress markers, mitochondrial function, and aging-hallmark biomarkers 4445. Whether to use direct GSH or a precursor strategy is a clinical decision for the prescribing physician.
Has glutathione been studied as a chemoprotectant?
Yes. Two notable randomized double-blind placebo-controlled trials reported reduced toxicity of platinum-based chemotherapy with IV glutathione: Smyth et al (1997) in cisplatin-treated ovarian cancer and Cascinu et al (2002) in oxaliplatin-based therapy for colorectal cancer 4041. These remain among the strongest controlled efficacy signals in the glutathione clinical literature, but they have not driven changes in standard oncology practice, and theoretical concerns about antioxidant interference with chemotherapy oxidative mechanisms remain. Oncology patients should consult their treating physician before starting any glutathione preparation.
Is IV glutathione safe for skin lightening?
No high-quality evidence supports IV glutathione for skin lightening, and significant safety concerns exist. The 2018 critical review by Sonthalia and colleagues cataloged regulatory warnings, including FDA enforcement against IV skin-lightening products and Philippine and Indian regulatory warnings, and concluded that the IV-glutathione skin-lightening market is not supported by high-quality efficacy evidence and operates outside appropriate compounded-medication use. A 2025 systematic review reached similar conclusions. RonanRx does not support compounded IV glutathione for cosmetic skin lightening 2829.
Clinician resource
Download the Glutathione Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[sechi1996] Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1996. PMID 8938817. (accessed 2026-05-07)
[hauser2009] Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders. 2009. PMID 19230029. (accessed 2026-05-07)
[mischley2015] Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Movement Disorders. 2015. PMID 26230671. (accessed 2026-05-07)
[mischley2016] Mischley LK, Conley KE, Shankland EG, Kavanagh TJ, Rosenfeld ME, et al. Central nervous system uptake of intranasal glutathione in Parkinson's disease. NPJ Parkinson's Disease. 2016. PMID 28725693. (accessed 2026-05-07)
[mischley2017] Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. Journal of Parkinson's Disease. 2017. PMID 28436395. (accessed 2026-05-07)
[honda2017] Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterology. 2017. PMID 28789631. (accessed 2026-05-07)
[lomaestro1995] Lomaestro BM, Malone M. Glutathione in health and disease: pharmacotherapeutic issues. Annals of Pharmacotherapy. 1995. PMID 8672832. (accessed 2026-05-07)
[lu2013] Lu SC. Glutathione synthesis. Biochimica et Biophysica Acta. 2013. PMID 22995213. (accessed 2026-05-07)
[wu2004] Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. The Journal of Nutrition. 2004. PMID 14988435. (accessed 2026-05-07)
[allen2011] Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine. 2011. PMID 21875351. (accessed 2026-05-07)
[richie2015] Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015. PMID 24791752. (accessed 2026-05-07)
[sinha2018] Sinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition. 2018. PMID 28853742. (accessed 2026-05-07)
[schmitt2015] Schmitt B, Vicenzi M, Garrel C, Denis FM. Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study. Redox Biology. 2015. PMID 26262996. (accessed 2026-05-07)
[zhang2012] Zhang H, Forman HJ. Glutathione synthesis and its role in redox signaling. Seminars in Cell & Developmental Biology. 2012. PMID 22504020. (accessed 2026-05-07)
[forman2014] Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radical Biology & Medicine. 2014. PMID 23747930. (accessed 2026-05-07)
[forman2016] Forman HJ. Redox signaling: An evolution from free radicals to aging. Free Radical Biology & Medicine. 2016. PMID 27393004. (accessed 2026-05-07)
[meister1995a] Meister A. Glutathione metabolism. Methods in Enzymology. 1995. PMID 7651209. (accessed 2026-05-07)
[meister1995b] Meister A. Mitochondrial changes associated with glutathione deficiency. Biochimica et Biophysica Acta. 1995. PMID 7599223. (accessed 2026-05-07)
[ballatori2009a] Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biological Chemistry. 2009. PMID 19166318. (accessed 2026-05-07)
[ballatori2009b] Ballatori N, Krance SM, Marchan R, Hammond CL. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Molecular Aspects of Medicine. 2009. PMID 18786560. (accessed 2026-05-07)
[aoyama2021] Aoyama K. Glutathione in the Brain. International Journal of Molecular Sciences. 2021. PMID 34065042. (accessed 2026-05-07)
[sies2019] Sies H. Selectively Addressing Mitochondrial Glutathione and Thioredoxin Redox Systems. Cell Chemical Biology. 2019. PMID 30901559. (accessed 2026-05-07)
[tam2013] Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. The Cochrane Database of Systematic Reviews. 2013. PMID 23852992. (accessed 2026-05-07)
[visca2008] Visca A, Bishop CT, Hilton SC, Hudson VM. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. Journal of Cystic Fibrosis. 2008. PMID 18499536. (accessed 2026-05-07)
[bishop2005] Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest. 2005. PMID 15653998. (accessed 2026-05-07)
[atkuri2007] Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Current Opinion in Pharmacology. 2007. PMID 17602868. (accessed 2026-05-07)
[sonthalia2016] Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian Journal of Dermatology, Venereology and Leprology. 2016. PMID 27088927. (accessed 2026-05-07)
[sonthalia2018] Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity?. Dermatology Practical & Conceptual. 2018. PMID 29445569. (accessed 2026-05-07)
[sarkar2025] Sarkar R, et al. Glutathione as a skin-lightening agent and in melasma: a systematic review. International Journal of Dermatology. 2025. PMID 39444151. (accessed 2026-05-07)
[sharma2022] Sharma DK, et al. Augmented Glutathione Absorption from Oral Mucosa and its Effect on Skin Pigmentation: A Clinical Review. Clinical, Cosmetic and Investigational Dermatology. 2022. PMID 36117769. (accessed 2026-05-07)
[phamhuy2008] Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. International Journal of Biomedical Science. 2008. PMID 23675073. (accessed 2026-05-07)
[lushchak2015] Lushchak VI. Free radicals, reactive oxygen species, oxidative stresses and their classifications. Ukrainian Biochemical Journal. 2015. PMID 27025055. (accessed 2026-05-07)
[loguercio2001] Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, et al. Relationship of blood trace elements to liver damage, nutritional status, and oxidative stress in chronic nonalcoholic liver disease. Biological Trace Element Research. 2001. PMID 11575681. (accessed 2026-05-07)
[aebi1991] Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European Journal of Clinical Investigation. 1991. PMID 1907548. (accessed 2026-05-11)
[witschi1992] Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. European Journal of Clinical Pharmacology. 1992. PMID 1362956. (accessed 2026-05-11)
[hagen1991] Hagen TM, Jones DP. Stimulation of glutathione absorption in rat small intestine by alpha-adrenergic agonists. FASEB Journal. 1991. PMID 1680764. (accessed 2026-05-11)
[borok1991] Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet. 1991. PMID 1676780. (accessed 2026-05-11)
[marrades1997] Marrades RM, Roca J, Barberà JA, de Jover L, MacNee W, Rodriguez-Roisin R. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. American Journal of Respiratory and Critical Care Medicine. 1997. PMID 9279219. (accessed 2026-05-11)
[smyth1997] Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Annals of Oncology. 1997. PMID 9261526. (accessed 2026-05-11)
[cascinu2002] Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2002. PMID 12177109. (accessed 2026-05-11)
[sekhar2011elderly] Sekhar RV, Patel SG, Guthikonda AP, Reid M, Balasubramanyam A, Taffet GE, Jahoor F. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. The American Journal of Clinical Nutrition. 2011. PMID 21795440. (accessed 2026-05-11)
[sekhar2011diabetes] Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A, Jahoor F. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011. PMID 20929994. (accessed 2026-05-11)
[kumar2021] Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clinical and Translational Medicine. 2021. PMID 33783984. (accessed 2026-05-11)
[kumar2023] Kumar P, Osahon OW, Sekhar RV. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023. PMID 35975308. (accessed 2026-05-11)
[pastore2014] Pastore A, Alisi A, di Giovamberardino G, Crudele A, Ceccarelli S, et al. Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. International Journal of Molecular Sciences. 2014. PMID 25407526. (accessed 2026-05-11)
[kern2011] Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR. A clinical trial of glutathione supplementation in autism spectrum disorders. Medical Science Monitor. 2011. PMID 22129897. (accessed 2026-05-11)
[arjinpathana2012] Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment. 2012. PMID 20524875. (accessed 2026-05-11)
[handog2016] Handog EB, Datuin MS, Singzon IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. International Journal of Dermatology. 2016. PMID 26148180. (accessed 2026-05-11)
[buonocore2016] Buonocore D, Grosini M, Giardina S, Michelotti A, Carrabetta M, Seneci A, Verri M, Dossena M, Marzatico F. Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione. Oxidative Medicine and Cellular Longevity. 2016. PMID 26649136. (accessed 2026-05-11)
[sies2017] Sies H, Berndt C, Jones DP. Oxidative Stress. Annual Review of Biochemistry. 2017. PMID 28441057. (accessed 2026-05-11)
Compounded Glutathione is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Glutathione, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Glutathione.
